网络周期非特异性药物 网络释义 1. 周期非特异性药物 周期非特异性药物(cell cycle non-specific drugs)直接破坏DNA结构以及影响其复制或转录功能的药物,如烷化剂、抗肿瘤抗 … 210.44.16.104|基于8个网页
声明: 本网站大部分资源来源于用户创建编辑，上传，机构合作，自有兼职答题团队，如有侵犯了你的权益，请发送邮箱到feedback@deepthink.net.cn 本网站将在三个工作日内移除相关内容,刷刷题对内容所造成的任何后果不承担法律上的任何义务或责任
Cancer is a group of diseases in which cells divide continuously and excessively. Cell division is tightly regulated by multiple evolutionarily conserved cell cycle control mechanisms, to ensure the production of two genetically identical cells. Cell cyc
Chromosome mis-segregation triggers cell cycle arrest through a mechanosensitive nuclear envelope checkpoint Hervé, Scelfo et al. show that chromosome mis-segregation induces mTORC2- and ATR-mediated p53 activation through a mechanosensitive checkpoint at the nuclear envelope triggered by altered heterochrom...
Positive cell isolation with Dynabeads magnetic beads In positive cell isolation using Dynabeads magnetic beads, the beads are coated with the specific antibody or ligand to bind to the target cells and the bead/cell complexes are pulled down using a magnet. The supernatant contains non-specific ce...
On the basis of knowledge about the cell cycle and gene expression regulation, the first therapeutic proteins were produced using mammalian cell cultures. The end of twentieth century and early twenty‐first century brought the progress in 3‐D cell culture technology and created the possibility of...
帕金森病(Parkinson’s disease, PD)是一种常见的神经退行性疾病,由中脑黑质区(Substantia nigra pars compacta,SNpc)多巴胺能(dopaminergic,DA)神经元变性引起,导致静止性震颤、运动迟缓等运动障碍1和非运动功能障碍(例如约30-85%的PD患者...
货号3002-MSM8-P1 CNY7,285.00 100 µg 下单后预计有货时间 17-Mar-2025 查看价格 批量或定制请求 Application Created with Sketch. 图:1/4 Granzyme B (NK/T-Cell Lymphoma Marker) Antibody (3002-MSM8-P1) in IHC (P) Formalin-fixed, paraffin-embedded human s...
ISCK03 (N-(4-imidazol-1-yl phenyl)sulfonamide)是stem-cell factor (SCF)/c-kit信号通路的细胞渗透性抑制剂。ISCK03抑制SCF介导的c-c-kit磷酸化和下游ERK磷酸化。 靶点 TargetValue SCF () c-Kit () 体外研究 Pretreatment of 501mel cells with ISCK03 inhibits SCF-induced c-kit phosphorylation dose ...
C. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat. Immunol. 21, 835–847 (2020). Article CAS PubMed PubMed Central Google Scholar Liu, S. et al. NK cell-based cancer immunotherapy: from basic biology to clinical development. J. Hematol. ...